🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Recruitingn/aAges 18 Years - 55 YearsMaleYale University
NCT01730781 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \[11C\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric di

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Males ages 18-55 * For cannabis users: * Willing to abstain from cannabis use for four weeks * For schizophrenia: * Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder * For prodrome for psychotic illness: * Meets SIPS criteria for prodromal syndrome * For family history positive: * First degree relative with alcoholism * For Post-Traumatic Stress Disorder * Meets DSM-IV-TR criteria for PTSD * For OUD * Meets DSM-IV-TR criteria for Opioid Use Disorder Exclusion Criteria: * Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group. * Presence of ferromagnetic metal in the body or heart pacemaker * Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits * Are claustrophobic
💊

What it tests

  • [11-C]OMAR
📍

Where

1 site
Connecticut Mental Health Center, Clinical Neuroscience Research Unit
New Haven, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy